As champagne dries at the Broad Institute and tears are wiped at the University of California, another CRISPR question remains unanswered: What becomes of the companies that picked sides?
Editas Medicine, which has aligned with the winning Broad, saw its share price rise more than 25 percent on Wednesday. Intellia Therapeutics, affiliated with UC, fell about 11 percent, while compatriot CRISPR Therapeutics dipped 24 percent.
About the Author Reprints
